Colorectal cancer screening using protected microRNAs
Journal of Gastrointestinal Oncology, 09/30/2011
Wall NR – The study demonstrate that exosomes prevent the RNase–dependent degradation of miRNAs. Indeed, fecal miRNA–based testing, performed on tumor–exosomes sloughed or shed into the stool, will allow molecular–based diagnosis that in time may also aid in therapy decisions and disease response surveillance leading to better management of colorectal cancer.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.